The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data
Abstract
In vivo imaging of amyloid burden with positron emission tomography (PET) provides a means for studying the pathophysiology of Alzheimer's and related diseases. Measurement of subtle changes in amyloid burden requires quantitative analysis of image data. Reliable quantitative analysis of amyloid PET scans acquired at multiple sites and over time requires rigorous standardization of acquisition protocols, subject management, tracer administration, image quality control, and image processing and analysis methods. We review critical points in the acquisition and analysis of amyloid PET, identify ways in which technical factors can contribute to measurement variability, and suggest methods for mitigating these sources of noise. Improved quantitative accuracy could reduce the sample size necessary to detect intervention effects when amyloid PET is used as a treatment end point and allow more reliable interpretation of change in amyloid burden and its relationship to clinical course.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 24, 2014
- Source ID
- 10.1016/j.jalz.2014.09.004
Entities
People
- Dawn Matthews
- Gregory Klein
- Joyce Suhy
- Lennart Thurfjell
- Mark E. Schmidt
- N. Scott Mason
- Norman L. Foster
- Patricia E. Cole
- Ping Chiao
- Richard Margolin
- Robert A. Koeppe
- Susan De Santi
- Susan Landau
- The Alzheimer’s Disease Neuroimaging Initiative*
- William J. Jagust
Organizations
- Biogen
- GE HealthCare
- Helen Wills Neuroscience Institute
- Janssen Pharmaceutica
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Northern California Institute for Research and Education
- Takeda Pharmaceutical Company
- University of Michigan
- University of Pittsburgh
- University of Utah